The therapeutic potential of curcumin for the treatment of glioblastoma multiforme

Cover Page

Cite item

Full Text

Abstract

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

About the authors

T. I. Kushnir

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Institute of Biochemical Technology and Nanotechnology, Peoples’ Friendship University of Russia

Author for correspondence.
Email: winard2@mail.ru
ORCID iD: 0000-0001-9626-6847

Build. 15, 24 Kashirskoe Shosse, Moscow 115478; Build. 2, 10 Miklukho-Maklaya St., Moscow 117198

Russian Federation

N. E. Arnotskaya

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0154-8604

Build. 15, 24 Kashirskoe Shosse, Moscow 115478

Russian Federation

I. A. Kudryavtsev

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-7588-1066
Build. 15, 24 Kashirskoe Shosse, Moscow 115478 Russian Federation

V. E. Shevchenko

Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0401-9900
Build. 15, 24 Kashirskoe Shosse, Moscow 115478 Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.